Lucid Denies Conducting SRY Gene Testing at Its Facilities
With reference to the article published on August 2, 2024, we wish to clarify that Lucid does not conduct Sex Determining Region Y chromosome gene testing (SRY gene) at any of its facilities. This specialised test is exclusively performed in genetic laboratories utilising advanced techniques.
The SRY gene test is primarily used to identify phenotypic alterations resulting from chromosomal abnormalities in adult males or females, known as Disorders of Sexual Development (DSD). For instance, in the recent Paris Olympics women's boxing tournament, accusations were raised against Ms Imane Khelif, alleging she was a biological man with an unfair advantage due to DSD related to the SRY gene.
According to scientific literature, the SRY gene test is employed to detect the presence or absence of the SRY gene in individuals with either a 46,XX karyotype and phenotypically normal male external genitalia, or a 46,XY karyotype and phenotypically normal female external genitalia. This test is a sophisticated molecular genetic procedure and is not typically utilised for foetal gender determination.
We hereby affirm that Lucid strictly adheres to all statutory and regulatory policies established by the relevant government and medical authorities.